Alzheimer’s drug

HHS finalizes rule easing seniors’ access to Medicare Savings Program … Fitch: More bad news ahead for life plan communities … Will new COVID vaccines get to those who need them most? … Lumbar...

A trial evaluating the combination therapy of a drug and an antioxidant shows promise in treating Alzheimer’s disease, according to a new report.

Older, discharged COVID patients have double the risk of dying vs. flu patients: study … Private insurers denying coverage for new Alzheimer’s drugs … After turning away from skilled nursing, Invesque...

CMS policy on new Alzheimer’s drugs restricts rural access: former senator … Bedbugs may spread MRSA: study … CIDRAP: Sporicidal disinfectants better against Candida Auris … Nearly 30 affected...

New trial data for lecanemab (Leqembi) supports traditional, or “full” federal approval, the agency’s advisers said Friday. The decision is a step toward possible expanded patient access.

For the first time, the FDA has approved a drug to treat agitation related to Alzheimer’s disease dementia. Patient advocates are hailing the news, but prescribing the drug, an antipsychotic, may put...

The experimental drug donanemab appears to halt the progression of Alzheimer’s disease and slow certain measures of clinical decline, new trial data show.

Budget proposal offers big money for nursing homes, elder care in Ohio … Louisiana legislators consider weakening brand new nursing home disaster plan rule … Small and rural providers continue to lag...

New data on Lilly’s experimental drug donanemab may influence CMS’s restrictive stance on coverage of this and other amyloid-busting Alzheimer’s treatments, a company executive says.

California man, 23, shot to death in nursing home bed, police say … Race, geographic disparities found in 30-day readmissions for people with dementia … On the Move: AMDA Names Michelle Zinnert new...